title: [New therapeutic strategies for multiple myeloma. Efficacy and cost-effectiveness analyses].
abstract: The objective of the present article is the review of the most important therapeutic innovations in the treatment of multiple myeloma in terms of efficacy and cost-effectiveness. Besides autologous transplant with peripheral-blood stem-cell, thalidomide establishes as one of the most powerful therapeutic tools in induction and maintenance treatment and together with lenalidomide and bortezomib as therapy for relapsing/refractory multiple myeloma. Considering, the last named situation thalidomide can be an adequate therapeutical option in combination with dexamethasone. Under a strictly pharmacoeconomic point of view, lenalidomide and bortezomib seem to be additional alternatives in patients previously treated with thalidomide.
authors.affiliation: Servicio de Farmacología Clínica, Clínica Universitaria de Navarra, Pamplona, Navarra. España. egquetglas@unav.es
authors.forename: Emilio
authors.initials: E
authors.lastname: García Quetglas
authors.forename: José Ramón
authors.initials: JR
authors.lastname: Azanza Perea
authors.forename: Ramón
authors.initials: R
authors.lastname: Lecumberri Villamediana
mesh_terms: D003362:Cost-Benefit Analysis; D006801:Humans; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000191:economics; D012008:Recurrence